🧠This Week in Neuroscience: AI-Redefined MS, $1B+ Epilepsy Deal, Home-Based Diagnostics & More
Stay informed with the latest neuroscience breakthroughs! In this week’s roundup, we spotlight major milestones in multiple sclerosis, epilepsy, spinal muscular atrophy, and myasthenia gravis. From AI-driven reclassification models and fast-tracked MS therapies to billion-dollar deals and groundbreaking gene treatments, this episode covers the most pivotal updates in neurological care.
📌 What’s Inside This Week’s Update
🧠AI redefines multiple sclerosis using data from 35,000+ MRIs
🚀 BioNxt fast-tracks thin-film cladribine with global patent strategy
🧩 China pioneers single-stage brain-spine tumor surgery with 71% resection rate
đź’¸ Jazz inks $1B+ licensing deal for epilepsy candidate SAN2355
👶 Risdiplam shows strong motor gains in SMA newborns, leading to FDA label expansion
🏡 AI-powered diagnostics go home-based for autism and ADHD in infants
💉 First-ever gene therapy for AADC successfully delivered at Texas Children’s
⚡ XEOMIN launches global Phase III migraine trials with 1,770 patients
🎯 VYVGART demonstrates efficacy in triple seronegative gMG trial
📢 Stay Ahead in Neuroscience Research!
âś… Like, share, and subscribe for weekly updates on neuroscience and breakthrough therapies
#Neuroscience #MultipleSclerosis #Epilepsy #GeneTherapy #AIinHealthcare #SMA #gMG #MigraineTreatment #FDAApproval #LucidQuest #ClinicalTrials #NeuroInnovation #HealthcareTechnology